NSC vs STRO · P/E 18, rev $12.12B vs rev $62.0M
Norfolk Southern Corporation (NSC) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported NSC revenue for 2024-12-31 was $12.12B. Net income was $2.62B. Revenue was down 0.3% from 2023-12-31 to 2024-12-31. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
NSC currently screens at market cap $60.10B and trailing P/E 18.2. STRO currently screens at market cap $470.8M.
Not investment advice. Open the NSC and STRO stock pages for the full models.
Not investment advice.